Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.

Nat Commun. 2019 Aug 15;10(1):3680. doi: 10.1038/s41467-019-11563-5.

2.

IRE1α-XBP1 signaling in leukocytes controls prostaglandin biosynthesis and pain.

Chopra S, Giovanelli P, Alvarado-Vazquez PA, Alonso S, Song M, Sandoval TA, Chae CS, Tan C, Fonseca MM, Gutierrez S, Jimenez L, Subbaramaiah K, Iwawaki T, Kingsley PJ, Marnett LJ, Kossenkov AV, Crespo MS, Dannenberg AJ, Glimcher LH, Romero-Sandoval EA, Cubillos-Ruiz JR.

Science. 2019 Jul 19;365(6450). pii: eaau6499. doi: 10.1126/science.aau6499.

PMID:
31320508
3.

Dendritic Cell Metabolism and Function in Tumors.

Giovanelli P, Sandoval TA, Cubillos-Ruiz JR.

Trends Immunol. 2019 Aug;40(8):699-718. doi: 10.1016/j.it.2019.06.004. Epub 2019 Jul 10. Review.

PMID:
31301952
4.

Somatic mutations and cell identity linked by Genotyping of Transcriptomes.

Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, Pastore A, Cubillos-Ruiz JR, Tam W, Hoffman R, Rabadan R, Scandura JM, Abdel-Wahab O, Smibert P, Landau DA.

Nature. 2019 Jul;571(7765):355-360. doi: 10.1038/s41586-019-1367-0. Epub 2019 Jul 3.

PMID:
31270458
5.

Tricarboxylic Acid Cycle Activity and Remodeling of Glycerophosphocholine Lipids Support Cytokine Induction in Response to Fungal Patterns.

Márquez S, Fernández JJ, Mancebo C, Herrero-Sánchez C, Alonso S, Sandoval TA, Rodríguez Prados M, Cubillos-Ruiz JR, Montero O, Fernández N, Sánchez Crespo M.

Cell Rep. 2019 Apr 9;27(2):525-536.e4. doi: 10.1016/j.celrep.2019.03.033.

6.

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.

Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1. Erratum in: Nat Commun. 2019 Aug 15;10(1):3680.

7.

PolyGlcNAc-containing exopolymers enable surface penetration by non-motile Enterococcus faecalis.

Ramos Y, Rocha J, Hael AL, van Gestel J, Vlamakis H, Cywes-Bentley C, Cubillos-Ruiz JR, Pier GB, Gilmore MS, Kolter R, Morales DK.

PLoS Pathog. 2019 Feb 11;15(2):e1007571. doi: 10.1371/journal.ppat.1007571. eCollection 2019 Feb.

8.

Endoplasmic Reticulum Stress Responses in Intratumoral Immune Cells: Implications for Cancer Immunotherapy.

Song M, Cubillos-Ruiz JR.

Trends Immunol. 2019 Feb;40(2):128-141. doi: 10.1016/j.it.2018.12.001. Epub 2019 Jan 3.

PMID:
30612925
9.

IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.

Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, Bettigole SE, Shin HR, Crowley MJP, Cerliani JP, Kossenkov AV, Motorykin I, Zhang S, Manfredi G, Zamarin D, Holcomb K, Rodriguez PC, Rabinovich GA, Conejo-Garcia JR, Glimcher LH, Cubillos-Ruiz JR.

Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. Epub 2018 Oct 10.

10.

Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation.

Zhang H, Freitas D, Kim HS, Fabijanic K, Li Z, Chen H, Mark MT, Molina H, Martin AB, Bojmar L, Fang J, Rampersaud S, Hoshino A, Matei I, Kenific CM, Nakajima M, Mutvei AP, Sansone P, Buehring W, Wang H, Jimenez JP, Cohen-Gould L, Paknejad N, Brendel M, Manova-Todorova K, Magalhães A, Ferreira JA, Osório H, Silva AM, Massey A, Cubillos-Ruiz JR, Galletti G, Giannakakou P, Cuervo AM, Blenis J, Schwartz R, Brady MS, Peinado H, Bromberg J, Matsui H, Reis CA, Lyden D.

Nat Cell Biol. 2018 Mar;20(3):332-343. doi: 10.1038/s41556-018-0040-4. Epub 2018 Feb 19.

11.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

12.

Endoplasmic Reticulum Stress Sensor IRE1α Enhances IL-23 Expression by Human Dendritic Cells.

Márquez S, Fernández JJ, Terán-Cabanillas E, Herrero C, Alonso S, Azogil A, Montero O, Iwawaki T, Cubillos-Ruiz JR, Fernández N, Crespo MS.

Front Immunol. 2017 Jun 19;8:639. doi: 10.3389/fimmu.2017.00639. eCollection 2017.

13.

Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.

Chae CS, Teran-Cabanillas E, Cubillos-Ruiz JR.

Cancer Immunol Immunother. 2017 Aug;66(8):969-977. doi: 10.1007/s00262-017-1958-2. Epub 2017 Feb 18. Review.

PMID:
28214928
14.

Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer.

Cubillos-Ruiz JR, Bettigole SE, Glimcher LH.

Cell. 2017 Feb 9;168(4):692-706. doi: 10.1016/j.cell.2016.12.004. Review.

15.

Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer.

Cubillos-Ruiz JR, Mohamed E, Rodriguez PC.

J Immunother Cancer. 2017 Jan 17;5:5. doi: 10.1186/s40425-016-0203-4. eCollection 2017. Review.

16.

Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy.

Cubillos-Ruiz JR, Glimcher LH.

Oncoimmunology. 2015 Oct 29;5(3):e1098802. eCollection 2016 Mar.

17.

State-of-the-art of regulatory dendritic cells in cancer.

Conejo-Garcia JR, Rutkowski MR, Cubillos-Ruiz JR.

Pharmacol Ther. 2016 Aug;164:97-104. doi: 10.1016/j.pharmthera.2016.04.003. Epub 2016 Apr 23. Review.

18.

Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment.

Cubillos-Ruiz JR, Bettigole SE, Glimcher LH.

Clin Cancer Res. 2016 May 1;22(9):2121-6. doi: 10.1158/1078-0432.CCR-15-1570. Epub 2016 Mar 15. Review.

19.

IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection.

Adoro S, Cubillos-Ruiz JR, Chen X, Deruaz M, Vrbanac VD, Song M, Park S, Murooka TT, Dudek TE, Luster AD, Tager AM, Streeck H, Bowman B, Walker BD, Kwon DS, Lazarevic V, Glimcher LH.

Nat Commun. 2015 Jun 25;6:7562. doi: 10.1038/ncomms8562.

20.

ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.

Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K, Ellenson LH, Caputo T, Lee AH, Conejo-Garcia JR, Glimcher LH.

Cell. 2015 Jun 18;161(7):1527-38. doi: 10.1016/j.cell.2015.05.025. Epub 2015 Jun 11.

21.

Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.

Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ.

Cancer Res. 2013 Jul 1;73(13):3842-51. doi: 10.1158/0008-5472.CAN-12-1974. Epub 2013 May 23.

22.

Reprogramming immune responses via microRNA modulation.

Cubillos-Ruiz JR, Rutkowski MR, Tchou J, Conejo-Garcia JR.

Microrna Diagn Ther. 2013 Apr 26;1(1). pii: 2013-0001.

23.

Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles.

Cubillos-Ruiz JR, Sempere LF, Conejo-Garcia JR.

Oncoimmunology. 2012 Sep 1;1(6):968-970.

24.

BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1α.

Rodriguez DA, Zamorano S, Lisbona F, Rojas-Rivera D, Urra H, Cubillos-Ruiz JR, Armisen R, Henriquez DR, Cheng EH, Letek M, Vaisar T, Irrazabal T, Gonzalez-Billault C, Letai A, Pimentel-Muiños FX, Kroemer G, Hetz C.

EMBO J. 2012 May 16;31(10):2322-35. doi: 10.1038/emboj.2012.84. Epub 2012 Apr 17.

25.

Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.

Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, Fiering S, Conejo-Garcia JR.

J Exp Med. 2012 Mar 12;209(3):495-506. doi: 10.1084/jem.20111413. Epub 2012 Feb 20.

26.

Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, Sempere LF, Conejo-Garcia JR.

Cancer Res. 2012 Apr 1;72(7):1683-93. doi: 10.1158/0008-5472.CAN-11-3160. Epub 2012 Feb 3.

27.

It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses.

Cubillos-Ruiz JR, Conejo-Garcia JR.

Cell Cycle. 2011 Feb 1;10(3):368-9. Epub 2011 Feb 1. No abstract available.

28.

Antifungal mechanisms by which a novel Pseudomonas aeruginosa phenazine toxin kills Candida albicans in biofilms.

Morales DK, Jacobs NJ, Rajamani S, Krishnamurthy M, Cubillos-Ruiz JR, Hogan DA.

Mol Microbiol. 2010 Dec;78(6):1379-92. doi: 10.1111/j.1365-2958.2010.07414.x. Epub 2010 Oct 18.

29.

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR.

Oncotarget. 2010 Sep;1(5):329-38.

30.

CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.

Nesbeth YC, Martinez DG, Toraya S, Scarlett UK, Cubillos-Ruiz JR, Rutkowski MR, Conejo-Garcia JR.

J Immunol. 2010 May 15;184(10):5654-62. doi: 10.4049/jimmunol.0903247. Epub 2010 Apr 16.

31.

Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.

Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR.

Cell Cycle. 2010 Jan 15;9(2):260-8. Epub 2010 Jan 26. Review.

32.

Nanomolecular targeting of dendritic cells for ovarian cancer therapy.

Cubillos-Ruiz JR, Fiering S, Conejo-Garcia JR.

Future Oncol. 2009 Oct;5(8):1189-92. doi: 10.2217/fon.09.101. Review. No abstract available.

33.

In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR.

Cancer Res. 2009 Sep 15;69(18):7329-37. doi: 10.1158/0008-5472.CAN-09-0835. Epub 2009 Sep 8.

34.

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR.

J Clin Invest. 2009 Aug;119(8):2231-44. doi: 10.1172/JCI37716. Epub 2009 Jul 13.

35.

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR.

Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3.

36.

PILAR is a novel modulator of human T-cell expansion.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Engle XA, Rigby WF, Pioli PA, Guyre PM, Conejo-Garcia JR.

Blood. 2008 Aug 15;112(4):1259-68. doi: 10.1182/blood-2007-12-130773. Epub 2008 Jun 12.

Supplemental Content

Loading ...
Support Center